Clinical practice guidelines for the diagnosis and management of Charcot-Marie-Tooth disease.

Autores de IDIVAL

• 

  Ana Lara Pelayo Negro

  Autor

  analara.pelayo@scsalud.es

Autores ajenos al IDIVAL

• Sivera Mascaró R
• García Sobrino T
• Horga Hernández A
• Alonso Jiménez A
• Antelo Pose A
• Calabria Gallego MD
• Casasnovas C
• Cemillán Fernández CA
• Esteban Pérez J
• Fenollar Cortés M
• Frasquet Carrera M
• Gallano Petit MP
• Giménez Muñoz A
• Gutiérrez Gutiérrez G
• Gutiérrez Martínez A
• Juntas Morales R
• Ciano-Petersen NL
• Martínez Ulloa PL
• Mederer Hengstl S
• Millet Sancho E
• Navacerrada Barrero FJ
• Navarrete Faubel FE
• Pardo Fernández J
• Pascual Pascual SI
• Pérez Lucas J
• Pino Mínguez J
• Rabasa Pérez M
• Sánchez González M
• Sotoca J
• Rodríguez Santiago B
• Rojas García R
• Turon-Sans J
• Vicent Carsí V
• Sevilla Mantecón T

Abstract

INTRODUCTION: Charcot-Marie-Tooth (CMT) disease is classified considering the neurophysiological and histological findings, the inheritance pattern and the underlying genetic defect. In recent years, with the advent of next generation sequencing, genetic complexity has increased exponentially, expanding the knowledge about disease pathways, and having an impact in clinical management. The aim of this guide is to offer recommendations for the diagnosis, prognosis, monitoring and treatment of this disease in Spain. MATERIAL AND METHODS: This consensus guideline has been developed by a multidisciplinary panel encompassing a broad group of professionals including neurologists, neuropediatricians, geneticists, rehabilitators, and orthopedic surgeons. RECOMMENDATIONS: The diagnosis is based in the clinical characterization, usually presenting with a common phenotype. It should be followed by an appropriate neurophysiological study that allows for a correct classification, specific recommendations are established for the parameters that should be included. Genetic diagnosis must be approached in sequentially, once the PMP22 duplication has been ruled out if appropriate, a next generation sequencing should be considered taking into account the limitations of the available techniques. To date, there is no pharmacological treatment that modifies the course of the disease, but symptomatic management is important, as are the rehabilitation and orthopedic considerations. The latter should be initiated early to identify and improve the patient's functional impairments, including individualized exercise guidelines, orthotic adaptation, and assessment of conservative surgeries such as tendon transpositions. The follow-up of patients with CMT is exclusively clinical, ancillary testing are not necessary in routine clinical practice.

Copyright © 2024 Sociedad Española de Neurología. Published by Elsevier España, S.L.U. All rights reserved.

Keywords

• Charcot-Marie-Tooth disease; Enfermedad de Charcot-Marie-Tooth; Espana; Hereditary neuropathy; Neuropatía hereditaria; Spain